Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
Zheng LiuMette JulsgaardXiao ZhuJennifer MartinMurray L BarclayNoel CranswickPeter R GibsonRichard B GearryJanine van der GiessenSusan J ConnorOurania RosellaAnne GrosenCatherine ToongEmma K FlanaganJantien W WieringaC Janneke van der WoudeSally J Bellnull nullPublished in: Journal of Crohn's & colitis (2022)
Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children.